Global Lung Cancer Therapeutics Market - 2022-2029

Global Lung Cancer Therapeutics Market - 2022-2029

Market Overview

The global lung cancer therapeutics market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Lung cancer is a type of cancer that develops in the tissues of the lungs, most commonly in the cells that line the airways. It is the leading cause of cancer death in both men and women.

Market Dynamics

The factors influencing the global lung cancer therapeutics market are the increasing research and development of new drugs and the growing prevalence of lung cancer.

The increasing research and development of new drugs is expected to drive the market growth

Hepatocellular carcinoma (HCC) is one of the world's deadliest diseases. Because of insufficient early diagnosis and few treatment options for patients with advanced-stage HCC, most patients with HCC have poor outcomes. These significant technological advancements have resulted in several significant breakthroughs, numerous clinical trials, and the FDA approval of multiple drugs. Regorafenib, lenvatinib, cabozantinib, and ramucirumab are multikinase inhibitors that the FDA approved for HCC between 2017 and 2019. The approval of lenvatinib and bevacizumab in combination with atezolizumab as two first-line treatment strategies has significantly changed HCC treatment options, as sorafenib was previously the only viable first-line treatment option for advanced HCC. Meanwhile, immune checkpoint blockade (ICB) therapy targeting programmed cell death-1 and its ligand (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has proven to be highly effective in the treatment of melanoma and non-small cell lung cancer, paving the way for immunotherapy for HCC. The FDA approved the anti-PD-1 antibodies nivolumab and pembrolizumab as second-line treatments for patients with HCC in 2017–2018. Furthermore, technology for extracting active substances from traditional Chinese medicine (TCM) therapies has advanced dramatically, making it easier to investigate TCM's pharmacological mechanisms. All these developments point to a bright future for HCC drug treatment.

For instance, on 28th, 2021, The US Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer who have received at least one prior systemic therapy tumors have a genetic mutation known as KRAS G12C. This is the first targeted therapy approved for tumors with any KRAS mutation, which accounts for about 25% of mutations in non-small cell lung cancers. In non-small cell lung cancers, KRAS G12C mutations account for about 13% of all mutations.

The side effects associated with liver cancer therapeutics are expected to hamper the market growth

Chemotherapy can have side effects because it kills cancer cells while harming healthy cells. Side effects can occur immediately following or a few days or weeks after chemotherapy. Chemotherapy side effects can appear months or even years later. Most side effects go away on their own or can be treated, but some can last for a long time or become permanent. The type of drug, the combination of drugs, the dose, how it's given, whether a patient is getting radiation at the same time, and the overall health will all influence the side effects of chemotherapy. Some of the most common side effects of lung cancer chemotherapy drugs are a low number of blood cells, vomiting, nausea, hair loss, diarrhea, fatigue, damage to the peripheral nerves, a decrease in appetite, sore Skin problems in the mouth, and throat, constipation.

COVID-19 Impact Analysis

The COVID-19 pandemic continues to be a threat to people all over the world, especially those who already have lung disease. As a result of the pandemic, lung cancer patients have faced numerous challenges. According to an article published in September 2020 at the Fifth Affiliated Hospital of Sun Yat-sen University titled The impact of the COVID-19 pandemic on lung cancer patients, approximately 95 patients out of 161 had delayed their return visit in April 2020, and 47 cases were finally designated as having delayed admission during the epidemic and having to discontinue or delay their regular anticancer treatments.

Segment Analysis

Based on disease type, Non-Small Cell Lung Cancer (NSCLC) is expected to dominate the market growth

NSCLC (non–small cell lung cancer) accounts for roughly 85% of all lung cancers. NSCLC is classified histologically into adenocarcinoma, squamous cell carcinoma (SCC) (see image below), and large cell carcinoma. Patients with NSCLC should have a complete staging workup to determine the extent of their disease, as stage influences treatment options. NSCLC is a sneaky disease that often goes unnoticed until it's too late. Early detection of symptoms may help to improve the outcome. At the time of diagnosis, 20% of patients have localised disease, 25% of patients have regional metastasis, and 55% of patients have distant spread of disease. The symptoms of cancer vary depending on where it is found. The more common two types of lung cancer are non-small cell lung cancer (NSCLC). According to the American Cancer Society, NSCLC accounts for 80 to 85 percent of lung cancers. NSCLC is divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different lung cells, are grouped as NSCLC because their treatment and prognoses (outlook) are often similar.

According to a report published by the Cancer Treatment Centers of America, lung adenocarcinoma is the most common type of lung cancer, accounting for 30% of all cases and roughly 40% of non-small cell lung cancer cases. January 2022 on Lung cancer types. According to the same source, squamous cell lung cancer accounts for roughly 30% of all non-small cell lung cancers and is frequently linked to smoking. The most common type of NSCLC is large-cell undifferentiated carcinoma, which accounts for 10% to 15% of all cases. Large-cell undifferentiated carcinoma has a proclivity for rapidly growing and spreading.

Geographical Analysis

North America region is expected to hold the largest market share in the global lung cancer therapeutics market

The growing number of people diagnosed with lung cancer is the primary driver of market growth. According to the American Society of Clinical Oncology's 2021 report, lung cancer will be diagnosed in 235,760 adults in the United States (US) (119,100 men and 116,6600 women). Lung cancer accounts for roughly 13% of all new cancer diagnoses. Lung cancer is the second most common cancer in men and women in the United States and the leading cause of cancer death. According to the report, 131,880 people will die from this disease in 2021 (69,410 men and 62,470 women).

Moreover, the increasing product approvals in this region is expected to drive the market growth. For instance, on 28th May 2021, LUMAKRASTM (sotorasib) was approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy and are locally advanced or metastatic, as determined by an FDA-approved test. Based on the overall response rate (ORR) and response duration, LUMAKRAS has received accelerated approval (DoR).

Competitive Landscape

The global lung cancer therapeutics market is highly competitive with mergers, acquisitions, and product launches. Some key players are AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech USA, Inc., Merck & Co, Pfizer Inc., Amgen Inc., Hoffmann-La Roche, Abbvie, Inc.

Pfizer Inc.

Overview: Pfizer Inc., headquartered on 42nd Street in Manhattan, New York City, is an American multinational pharmaceutical and biotechnology corporation. The company was founded in 1849.

Product Portfolio: LORBRENA is a prescription drug used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of their body and is caused by a mutation in the anaplastic lymphoma kinase (ALK) gene.

Key Development: On 3rd March, The US Food and Drug Administration (FDA) has approved Pfizer Inc.'s supplemental New Drug Application (sNDA) for LORBRENA (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

Why Purchase the Report?

Visualize the composition of the global lung cancer therapeutics composition market segmentation by treatment, disease type, and distribution channel, highlighting the key commercial assets and players.

Identify commercial opportunities in global lung cancer therapeutics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global lung cancer therapeutics market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global lung cancer therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers